Choose a language and wait for the translated text.
Shots:
The US FDA has cleared MiniMed Fit, the company’s first tubeless insulin pump, for people with T1D & T2D aged ≥7yrs., combining up to 7-day wear, a 300-unit insulin capacity, app control & SmartGuard technology
The system automatically adjusts insulin delivery and can deliver correction doses every 5min., with Meal Detection technology to deliver additional insulin when a meal dose is missed or underestimated, and at launch will offer Simplera Sync (up to 7-day wear) & Instinct (made by Abbott; up to 15-day wear) sensors
A US phased rollout is expected in spring 2027, following an early customer experience phase in MiniMed’s Q4 FY2027, with availability planned through the pharmacy channel
Ref: PR Newswire | Image: MiniMed | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
The post The US FDA Clears MiniMed Fit, a Tubeless Insulin Pump with Up to Seven-Day Wear appeared first on PharmaShots.